Predictor factor of survival in advanced hepatocellular carcinoma treated with sorafenib ∼a multicenter study∼

被引：0
|
作者：
Ogawa, Chikara [1 ,6 ]
Morita, Masahiro [1 ]
Omura, Akina [1 ]
Shibatoge, Mitsushige [1 ]
Tsutsui, Akemi [2 ]
Senoh, Tomonori [2 ]
Nagano, Takuya [2 ]
Takaguchi, Kouichi [2 ]
Tani, Joji [3 ]
Morishita, Asahiro [3 ]
Yoneyama, Hirohito [3 ]
Masaki, Tsutomu [3 ]
Moriya, Akio [4 ]
Ando, Masaharu [4 ]
Deguchi, Akihiro [5 ]
Kudo, Masatoshi [6 ]
机构：
[1] Takamatsu Red Cross Hosp, Dept Gastroenterol & Hepatol, Takamatsu, Kagawa, Japan
[2] Kagawa Prefectural Cent Hosp, Dept Hepatol, Takamatsu, Kagawa, Japan
[3] Kagawa Univ, Fac Med, Dept Gastroenterol & Neurol, Takamatsu, Kagawa, Japan
[4] Mitoyo Gen Hosp, Dept Gastroenterol, Kanonji, Japan
[5] Kagawa Rosai Hosp, Dept Gastroenterol, Marugame, Japan
[6] Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, Higashiosaka, Osaka, Japan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O1-6-4
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Hepatocellular carcinoma in advanced stage - improve survival with Sorafenib
    不详
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2009, 47 (06): : A2 - A4
  • [22] A multicenter analysis of prognostic factors in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib.
    Smith, Alan D.
    Chan, Kelvin K.
    Lim, Howard John
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] Severe Fatigue is an Important Factor in the Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib
    Qiu, Xuan
    Li, Manjiang
    Wu, Liqun
    Xin, Yang
    Mu, Siyu
    Li, Tianxiang
    Song, Kangjian
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 7983 - 7992
  • [24] Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Study
    Ogawa, Chikara
    Morita, Masahiro
    Omura, Akina
    Noda, Teruyo
    Kubo, Atsushi
    Matsunaka, Toshihiro
    Tamaki, Hiroyuki
    Shibatoge, Mitsushige
    Tsutsui, Akemi
    Senoh, Tomonori
    Nagano, Takuya
    Takaguchi, Kouichi
    Tani, Joji
    Morishita, Asahiro
    Yoneyama, Hirohito
    Masaki, Tsutomu
    Moriya, Akio
    Ando, Masaharu
    Deguchi, Akihiro
    Kokudo, Yasutaka
    Minami, Yasunori
    Ueshima, Kazuomi
    Sakurai, Toshiharu
    Nishida, Naoshi
    Kudo, Masatoshi
    ONCOLOGY, 2017, 93 : 113 - 119
  • [25] Comparison of prognostic models in predicting survival of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: a multicenter cohort study
    Marasco, G.
    Colecchia, A.
    Reggiani, M. L. Bacchi
    Dajiti, E.
    Ravaioli, F.
    Avanzato, F.
    Trevisani, F.
    Festi, D.
    DIGESTIVE AND LIVER DISEASE, 2020, 52 : E50 - E50
  • [26] COMPARISON OF PROGNOSTIC MODELS IN PREDICTING SURVIVAL OF PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA UNDERGOING SORAFENIB TREATMENT: A MULTICENTER COHORT STUDY
    Marasco, G.
    Colecchia, A.
    Reggiani, Bacchi M. L.
    Dajti, E.
    Ravaioli, F.
    Avanzato, F.
    Trevisani, F.
    Festi, D.
    DIGESTIVE AND LIVER DISEASE, 2020, 52 : S157 - S157
  • [27] Comparison of prognostic models in predicting survival of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: a multicenter cohort study
    Marasco, Giovanni
    Colecchia, Antonio
    Reggiani, Maria Letizia Bacchi
    Dajti, Elton
    Ravaioli, Federico
    Avanzato, Francesca
    Trevisani, Franco
    Festi, Davide
    JOURNAL OF HEPATOLOGY, 2020, 73 : S377 - S378
  • [28] Prospective Italian multicenter field-practice study with sorafenib for advanced hepatocellular carcinoma
    Iavarone, M.
    Cabibbo, G.
    Sangiovanni, A.
    Camma, C.
    Borghi, A.
    Zavaglia, C.
    Grieco, A.
    Granito, A.
    Airoldi, A.
    Biolato, M.
    Di Marco, V.
    Piscaglia, F.
    Pinzello, G. B.
    Racco, S.
    Bolondi, L.
    Craxi, A.
    Colombo, M.
    DIGESTIVE AND LIVER DISEASE, 2011, 43 : S65 - S65
  • [29] Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan
    Ogasawara, Sadahisa
    Ooka, Yoshihiko
    Itokawa, Norio
    Inoue, Masanori
    Okabe, Shinichiro
    Seki, Atsuyoshi
    Haga, Yuki
    Obu, Masamichi
    Atsukawa, Masanori
    Itobayashi, Ei
    Mizumoto, Hideaki
    Sugiura, Nobuyuki
    Azemoto, Ryosaku
    Kanayama, Kengo
    Kanzaki, Hiroaki
    Maruta, Susumu
    Maeda, Takahiro
    Kusakabe, Yuko
    Yokoyama, Masayuki
    Kobayashi, Kazufumi
    Kiyono, Soichiro
    Nakamura, Masato
    Saito, Tomoko
    Suzuki, Eiichiro
    Nakamoto, Shingo
    Yasui, Shin
    Tawada, Akinobu
    Chiba, Tetsuhiro
    Arai, Makoto
    Kanda, Tatsuo
    Maruyama, Hitoshi
    Kato, Naoya
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (01) : 172 - 180
  • [30] Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study
    Nakano, Masahito
    Tanaka, Masatoshi
    Kuromatsu, Ryoko
    Nagamatsu, Hiroaki
    Tajiri, Nobuyoshi
    Satani, Manabu
    Niizeki, Takashi
    Aino, Hajime
    Okamura, Shusuke
    Iwamoto, Hideki
    Shimose, Shigeo
    Shirono, Tomotake
    Koga, Hironori
    Torimura, Takuji
    CANCER MEDICINE, 2015, 4 (12): : 1836 - 1843
12345